Investment Rating - The report assigns a positive investment rating to the company, indicating a favorable outlook for the next six months [1]. Core Insights - The company has turned profitable for the first time, with a reported net profit of 642.47 million HKD in 2025, marking a significant increase of 245.81% compared to the previous year [7]. - The revenue for 2025 reached 2.37491 billion HKD, reflecting a growth rate of 135.27% [2]. - Strong sales growth of the drug Aobutini, which generated 1.41 billion HKD in 2025, up by 41% [7]. - The company has successfully licensed Aobutini to Zenas BioPharma, with a total transaction amount exceeding 2 billion USD, setting a record for external licensing in China's small molecule field [7]. - The company’s pipeline is entering a harvest phase, with multiple potential products progressing through clinical trials [7]. Financial Summary - The projected revenues for 2026, 2027, and 2028 are estimated at 20.2 billion HKD, 24.4 billion HKD, and 28.4 billion HKD respectively [9]. - The expected earnings per share (EPS) for 2026, 2027, and 2028 are 0.26 HKD, 0.29 HKD, and 0.32 HKD respectively [2]. - The net asset return (ROE) is projected to be 5.53% in 2026, increasing to 6.18% by 2028 [2]. - The price-to-earnings (PE) ratio is expected to decrease from 48.37 in 2026 to 38.21 in 2028 [2]. Product Pipeline and Development - Aobutini is expected to submit a market application for ITP in the first half of 2026, with several other clinical trials for various indications also underway [7]. - The company has two TYK2 inhibitors, with ongoing clinical trials for multiple conditions, including moderate to severe atopic dermatitis and vitiligo [7]. - The company is advancing multiple antibody-drug conjugate (ADC) projects, with IND approvals and clinical trials planned for 2026 [7].

Investment Rating - The report maintains a "Buy" rating for the company with a current price of HKD 6.85 [1] Core Insights - The company has shown steady profit growth and high dividend payouts, with a proposed final dividend of HKD 0.19 and a special dividend of HKD 0.10, leading to a total dividend of HKD 0.62 per share for 2025, resulting in a dividend payout ratio of approximately 99% [7] - The core shipping services, particularly in coatings and ship trading agency revenues, have increased, while general trade has been gradually divested, enhancing overall profit margins [7] - The company’s financial income has decreased by 20% due to falling deposit interest rates, but it still holds a net cash position of HKD 58.17 billion as of December 31, 2025 [7] Revenue and Profit Forecast - The company is expected to achieve revenues of HKD 37.7 billion, HKD 38.5 billion, and HKD 39.3 billion for the years 2026, 2027, and 2028 respectively, with attributable net profits projected at HKD 8.4 billion, HKD 9 billion, and HKD 9.5 billion for the same years [10] - The revenue growth rates are forecasted at 2.17% for 2026, 1.68% for 2027, and 2.10% for 2028, while net profit growth rates are expected to be 8.91%, 6.79%, and 6.03% respectively [2][10] Business Segment Performance - The shipping equipment and spare parts segment is projected to generate revenues of HKD 1.68 billion in 2026, with a year-on-year growth of 5% [9] - The coatings segment is expected to see a decline in revenue to HKD 1.60 billion in 2026, reflecting a decrease of 2% year-on-year [9] - The insurance consulting segment is anticipated to grow to HKD 227.9 million in 2026, with a steady growth rate of 2% [9] - The ship trading agency segment is forecasted to achieve revenues of HKD 169.1 million in 2026, with a significant growth of 10% year-on-year [9]

Domestic Developments - The long-term care insurance system is accelerating its implementation, aiming for nationwide coverage by the end of 2028, benefiting approximately 35 million disabled elderly individuals[15] - The "Token" has been officially named "词元," marking a significant step in the digital economy, with daily usage surpassing 140 trillion, a growth of over 1000 times since early 2024[11] - The 2026 Boao Forum predicts Asia's economic growth rate at 4.5%, slightly lower than 2025's 4.7%, but still leading globally amid uncertainties[13] International Developments - Trump announced negotiations with Iran, but significant differences in conditions may lead to a complicated negotiation process, with Brent crude oil prices dropping by 10.9% to $99.94 per barrel following his statements[17] - Japan's February CPI growth slowed to 1.3%, the lowest since March 2022, while the manufacturing PMI for March fell to 51.4, indicating a cooling economic sentiment[18] - The Eurozone's March composite PMI dropped to 50.5, the lowest since May 2022, with the European Central Bank signaling a strong likelihood of interest rate hikes due to rising energy prices[22] High-Frequency Data - Brent crude oil and iron ore prices increased by 1.19% and 1.14% week-on-week, while copper prices fell by 3.28%[24] - Real estate sales rose by 16.37% week-on-week, indicating a rebound in the housing market[24] - The price of domestic polysilicon dropped by 8.49% week-on-week, reflecting volatility in emerging industries[24]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified for the next six months [1]. Core Insights - The company reported a revenue of 2.02 billion yuan for 2025, representing a year-on-year growth of 49.07%. The net profit attributable to the parent company was 147.17 million yuan, up 47.86% year-on-year. For Q4 2025, the company expects a revenue of 649 million yuan, a 50.12% increase year-on-year, and a net profit of 39 million yuan, reflecting a 140.15% year-on-year growth [8]. - The company plans to raise up to 970 million yuan through convertible bonds to invest in high-end equipment manufacturing projects and to supplement working capital [8]. - The growth in revenue is primarily driven by increased deliveries of electric drive system rotor and stator products, as well as wind power industry components [8]. Financial Summary - Revenue projections for the company are as follows: 1.36 billion yuan in 2024, 2.02 billion yuan in 2025, 2.57 billion yuan in 2026, and 3.24 billion yuan in 2027, with growth rates of 19.26%, 49.07%, 27.03%, and 26.30% respectively [3]. - The net profit attributable to the parent company is expected to be 99.54 million yuan in 2024, 147.17 million yuan in 2025, 211.37 million yuan in 2026, and 280.90 million yuan in 2027, with growth rates of -24.85%, 47.84%, 43.63%, and 32.89% respectively [3]. - The earnings per share (EPS) are projected to be 0.45 yuan in 2024, 0.67 yuan in 2025, 0.96 yuan in 2026, and 1.28 yuan in 2027 [3]. Investment Opportunities - The company is expanding its product offerings in the electric drive system and wind power sectors, which are expected to drive significant revenue growth. The electric drive system products have already seen a revenue increase of 280.62% year-on-year in the first three quarters [8]. - The company is also venturing into new industries such as robotics and semiconductor cooling solutions, which are anticipated to open up additional growth avenues [8].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 11.57, based on a 10x PE valuation for 2026 [1][10]. Core Insights - The company achieved a revenue of HKD 97.63 billion in 2025, representing a year-on-year growth of 9.6%. The net profit attributable to the parent company was HKD 13.53 billion, up 28.7% year-on-year [7]. - The cloud computing segment showed strong growth, with revenue reaching HKD 5.08 billion, a 29.1% increase year-on-year. The company has established deep collaborations with major cloud providers like Amazon, Alibaba Cloud, and Huawei Cloud, with respective growth rates of 120%, 38%, and 25% for their services [7]. - The company is focusing on a dual-track computing ecosystem, combining domestic and overseas markets, with significant growth in Southeast Asia, where revenue reached HKD 35.75 billion, a 16.6% increase year-on-year, accounting for 37% of total revenue [7]. Financial Performance - Revenue projections for 2026-2028 are estimated at HKD 110.17 billion (up 12.9%), HKD 122.52 billion (up 11.2%), and HKD 134.22 billion (up 9.6%) respectively. The net profit for the same period is projected to be HKD 16.66 billion (up 22.9%), HKD 19.58 billion (up 17.8%), and HKD 22.61 billion (up 15.4%) [9][10]. - The company's operating efficiency has improved, with inventory days decreasing from 48 to 45 days and accounts receivable days from 72 to 69 days [7]. Business Segments - The enterprise systems segment is expected to grow at a compound annual growth rate (CAGR) of 13% over the next three years, while the consumer electronics segment is projected to grow at a CAGR of 4% [8]. - The cloud computing business is anticipated to grow at a robust CAGR of approximately 37% due to strong demand for AI cloud services and deepening partnerships with leading cloud providers [8].

Investment Rating - The report maintains a "Buy" rating for ZTO Express (2057.HK) [1] Core Insights - ZTO Express has launched a share repurchase plan with a target of over 10% annual growth in volume [1] - The company achieved total revenue of approximately 49.1 billion CNY in 2025, representing a year-on-year growth of 10.9% [7] - The company’s market share in the express delivery industry remains the highest at 19.4%, maintaining its leading position for ten consecutive years [7] - The company expects its package volume for 2026 to be between 42.37 billion and 43.52 billion, indicating a growth of 10% to 13% [7] - ZTO Express reported a robust operating cash flow of nearly 12 billion CNY in 2025 and announced a stock repurchase plan totaling 15 billion USD (approximately 103 billion CNY) [7] Financial Summary - Revenue projections for ZTO Express from 2026 to 2028 are estimated at 53.93 billion CNY, 59.77 billion CNY, and 66.85 billion CNY respectively, with net profit estimates of 9.25 billion CNY, 11.04 billion CNY, and 12.99 billion CNY [10][11] - The earnings per share (EPS) is projected to be 12.02 CNY, 14.34 CNY, and 16.87 CNY for the years 2026, 2027, and 2028 respectively [10][11] - The company’s gross margin is expected to improve from 25.31% in 2025 to 27.39% in 2028 [10] - The price-to-earnings (P/E) ratio is projected to decrease from 14.17 in 2025 to 9.91 in 2028, indicating a potentially attractive valuation [10]

Investment Rating - The report does not provide a specific investment rating for the company, but it indicates a focus on product iteration and growth potential in the future [1]. Core Insights - The company, Aimeike (爱美客), experienced a revenue decline of 18.94% in 2025, with total revenue of 2,452.62 million yuan and a net profit attributable to the parent company of 1,291.02 million yuan, down 34.05% year-on-year [7]. - The report highlights the pressure on core products, particularly solution and gel categories, which saw revenue declines of 27.48% and 26.82% respectively due to macroeconomic conditions and industry competition [7]. - New product contributions include 208 million yuan from the newly launched AestheFill product and expectations for further growth from upcoming products like Powerfill and a minoxidil solution approved in September 2025 [7][8]. - The company plans to increase investment in research and development, particularly in the area of semaglutide products for weight management [7]. Financial Summary - Revenue projections for 2026-2028 are as follows: 2,794.22 million yuan in 2026 (up 13.93%), 3,199.54 million yuan in 2027 (up 14.51%), and 3,555.44 million yuan in 2028 (up 11.12%) [2]. - Net profit forecasts for the same period are 1,477.14 million yuan in 2026 (up 14.42%), 1,711.13 million yuan in 2027 (up 15.84%), and 1,936.69 million yuan in 2028 (up 13.18%) [2]. - The report anticipates earnings per share (EPS) to increase from 4.27 yuan in 2025 to 6.40 yuan in 2028, with corresponding price-to-earnings (PE) ratios decreasing from 28 to 19 [2][10]. Business Segment Performance - Revenue from solution injection products is expected to recover with growth rates of 8.1% in 2026, 7.1% in 2027, and 6.1% in 2028, while gel products are projected to grow at similar rates [9]. - The newly introduced freeze-dried powder products are expected to see significant growth, with revenue increasing by 64.8% in 2026 and 52.3% in 2027 [9]. - Other business segments are also projected to perform well, with expected revenue growth rates of 35% in 2026, 25% in 2027, and 15% in 2028 [9].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of —— yuan over the next six months [1]. Core Insights - The company's main business has shown a recovery with significant net profit growth, and the introduction of Cordyceps has opened new growth opportunities [1]. - In 2025, the company achieved a revenue of 2.098 billion yuan, representing an 8.43% year-on-year increase, and a net profit attributable to the parent company of 335 million yuan, reflecting a remarkable growth of 161.63% [7]. - The strong performance is attributed to the stabilization and recovery of the edible mushroom industry starting in the second half of 2025, alongside robust performance in the company's core business [7]. Summary by Sections Financial Performance - In 2025, the company reported a revenue of 2,098 million yuan, with a year-on-year growth of 8.43%. The net profit attributable to the parent company was 335 million yuan, marking a 161.63% increase. The adjusted net profit after excluding non-recurring items was 304 million yuan, up 231.50% [7]. - The fourth quarter of 2025 saw a revenue of 623 million yuan and a net profit of 131 million yuan [7]. Business Segments - The company's two core businesses, the double-caps mushroom and the golden needle mushroom, performed well. The double-caps mushroom, as the main profit source, saw a revenue of 1,248 million yuan, up 15.74%, with a stable gross margin of 36.74% [7]. - The golden needle mushroom business, benefiting from price stabilization in the second half of 2025, turned profitable despite a revenue decline of 3.07% to 812 million yuan. The gross margin improved by 11.91 percentage points to 16.88% due to a significant reduction in operating costs [7]. Market Position and Strategy - The company ranks among the top in the industrial scale of factory-based edible mushroom production, which enhances its economies of scale. The product structure has been optimized, with the double-caps mushroom revenue share increasing to 59.49% and the golden needle mushroom share at 38.70% [7]. - The company has made significant progress in cost control, with financial expenses decreasing by 41.68% year-on-year, primarily due to lower loan rates and increased capitalization of interest [7]. Future Outlook - The company is actively expanding into high-value new categories, with Cordyceps expected to become a new growth engine. In 2025, the Cordyceps business generated revenue of 21.87 million yuan, marking the transition from planning to actual output [7]. - The earnings per share (EPS) for 2026-2028 are projected to be 0.98 yuan, 1.07 yuan, and 1.19 yuan, respectively, with corresponding dynamic price-to-earnings ratios of 18, 16, and 15 times [7].

Group 1 - The report emphasizes a defensive strategy in a volatile market, with a preference for short-duration products, as evidenced by the net inflows into various bond ETFs [2][5][6] - Last week, the net inflows for interest rate bond ETFs, credit bond ETFs, and convertible bond ETFs were -1.457 billion, 5.023 billion, and -2.241 billion respectively, leading to a total net inflow of 1.325 billion for bond ETFs [5][6] - The total scale of bond ETFs reached 725.34 billion as of March 20, 2026, reflecting a decrease of 0.10% from the previous week and a 12.53% decline since the beginning of the year [5][6] Group 2 - Short-term products, such as short-term financing and urban investment bond ETFs, have seen significant net inflows of 5.230 billion and 1.537 billion respectively, indicating a strong market preference for these assets [6][7] - The report forecasts a gradual increase in government bond supply due to a positive fiscal policy stance for 2026, while the pace of interest rate cuts may be delayed due to inflation concerns and strong economic data from early 2026 [7] - Caution is advised regarding the accumulation of long-duration products, with a focus on defensive products that offer stable coupon yields and liquidity advantages [7] Group 3 - The report notes that the net inflow of short-duration products is driven by a "deposit substitution" effect due to stricter self-discipline in interbank interest rates [6][7] - The net outflows from convertible bond ETFs were significant, totaling -2.241 billion, as the equity market showed no clear signs of reversal [6][7] - The report highlights that the recent adjustments in the PCF list for credit bond ETFs indicate a focus on bonds with shorter durations, with average modified durations of 3.03 years and 3.84 years for newly added bonds [6][7][46]

Investment Rating - The report does not specify a clear investment rating for the company [1] Core Insights - The company achieved a revenue of 6.70 billion yuan in 2025, representing a year-on-year increase of 8.83%, and a net profit attributable to the parent company of 1.74 billion yuan, up 11.66% year-on-year [8] - The core business of "Ejiao and related products" generated revenue of 6.20 billion yuan, growing by 11.80% year-on-year, while the "other medicines and health products" segment saw a significant increase of 63.65% to 386 million yuan [8] - The company is expanding into new health segments through acquisitions, such as Inner Mongolia Alashan Cistanche Group and Dongfeng Maji Pharmaceutical [8] - The gross profit margin for 2025 was 73.47%, with a slight increase of 1.05 percentage points year-on-year [8] Financial Performance Summary - Revenue projections for 2026-2028 are 7.70 billion yuan, 8.79 billion yuan, and 9.83 billion yuan, with growth rates of 14.86%, 14.27%, and 11.75% respectively [3][12] - Net profit attributable to the parent company is expected to reach 2.20 billion yuan in 2026, 2.58 billion yuan in 2027, and 2.96 billion yuan in 2028, with corresponding growth rates of 26.25%, 17.30%, and 14.84% [3][12] - The company plans to maintain a high dividend payout, with a total cash return to shareholders of 1.82 billion yuan in 2025, representing 104.6% of the net profit [8] Business Segment Analysis - The pharmaceutical industrial segment is projected to generate revenue of 7.00 billion yuan in 2026, with a stable gross margin of 75% [11] - The "other medicines and health products" segment is expected to grow significantly, with revenue forecasts of 580 million yuan in 2026, 840 million yuan in 2027, and 1.09 billion yuan in 2028, maintaining a gross margin of 70% [11] - The donkey breeding and trading business is anticipated to decline, with revenue projections of 60 million yuan for 2026, remaining stable thereafter [11]